---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089376"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:23:10.017707+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M

## Summary
- Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.
- MVE China revenue fell 67% YoY ($5.8M decline); slower client ramps also hit Biopharma/Pharma segment.
- Bioservices revenue rose 38% to $3.2M; commercial therapy revenue up 9.2% to $4.3M.
- Adjusted EBITDA was -$1.5M, down $7.5M YoY from $6.0M; net loss widened to $18.4M from $9.2M.
- FY2023 revenue guidance $233-243M; cash & short-term investments $504.7M at June 30.

## SEC filing metadata
- accession: 0001104659-23-089376
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/0001104659-23-089376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/tm2323346d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089376
- JSON: https://secwatch.observer/filing/0001104659-23-089376.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089376.txt

## Key facts
- Earnings Releases
  Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $57.0 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $57.0 million
  - Result: reported results
  source text: --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2323346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2023 Financial Results § Second quarter revenue of $57 million, in line with previously announced preliminary results § Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/0001104659-23-089376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.